Practice-changing trial results for advanced melanoma skin cancer

Determining the optimal treatment sequence for patients with BRAF V600 mutant metastatic melanoma was the focus of the DREAMseq phase 3 clinical trial. The combination of nivolumab and ipilimumab (N/I), followed by the combination of dabrafenib and trametinib (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%). Today, researchers from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) presented the findings at the Inaugural American Society of Clinical Oncology Virtual Plenary Series. The National Cancer Institute (NCI), part of the National Institutes of Health, sponsored the trial.,Determining the optimal treatment sequence for patients with BRAF V600 mutant metastatic melanoma was the focus of the DREAMseq phase 3 clinical trial. The combination of nivolumab and ipilimumab (N/I), followed by the combination of dabrafenib and trametinib (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%). Today, researchers from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) presented the findings at the Inaugural American Society of Clinical Oncology Virtual Plenary Series. The National Cancer Institute (NCI), part of the National Institutes of Health, sponsored the trial.

Leave a Reply